Randomised Clinical Trial Study: The Combination of Vitamin D and Curcumin Piperine Attenuates Disease Activity and Pro-inflammatory Cytokines Levels Insystemic Lupus Erythematosus Patients

被引:3
|
作者
Wahono, Cesarius Singgih [1 ]
Susianti, Hani [2 ]
Hakim, Arif Luqman [1 ]
Rosita, Firdha [1 ]
Pratama, Mirza Zaka [1 ]
Rahman, Perdana Aditya [1 ]
Anshory, Muhammad [3 ]
机构
[1] Univ Brawijaya, Saiful Anwar Gen Hosp, Fac Med, Dept Internal Med,Rheumatol Div, Malang, Indonesia
[2] Univ Brawijaya, Saiful Anwar Gen Hosp, Fac Med, Dept Clin Pathol, Malang, Indonesia
[3] Univ Brawijaya, Saiful Anwar Gen Hosp, Fac Med, Dept Internal Med,Allergy & Immunol Div, Malang, Indonesia
关键词
Systemic lupus erythematosus; vitamin D; curcumin; piperine; disease activity; inflammatory cytokines;
D O I
10.2174/0115733971276106231226071002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Curcumin-piperine might synergise with vitamin D to induce clinical remission in patients with systemic lupus erythematosus (SLE). Objective To observe the improvement of patients with SLE clinically and the levels of inflammatory cytokines after receiving supplements of curcumin-piperine and cholecalciferol (Vitamin D3). Methods Forty-five female SLE patients were included in a three-month double-blind, randomized controlled trial. Participants were classified into: Group I (400 IU cholecalciferol + placebo three times daily, n = 15), Group II (600 mg curcumin + 15,800 m piperine once daily and three times daily placebo, n = 15), and Group III (cholecalciferol 400 IU three times and 600 mg curcumin + 15,800 mg piperine once a day, n = 15). Mexican SLE disease activity score (Mex-SLEDAI), fatigue severity scale (FSS), TGF-beta, and IL-6 levels were measured from all patients before and after the treatments. Results Mex-SLEDAI, FSS, and IL-6 were reduced significantly, while TGF-beta serum levels were increased in all groups after the treatments (p <0.05). Changes in Mex-SLEDAI score (p = 0.003 and p = 0.008), FSS (p = 0.001 and p <0.001), and TGF-beta (p = 0.003 and p = 0.004) serum levels were significantly higher in group III compared to the group I or group II. On the other hand, changes in Mex-SLEDAI, FSS, IL-6, and TGF-beta serum levels were similar between groups I and II. Conclusion Although vitamin D or curcumin-piperine alone could improve the clinical outcome and cytokines levels in SLE, curcumin-piperine combined with vitamin D had the best outcome in improving the disease activity and cytokines levels among patients with SLE. (ClinicalTrials.gov number, NCT05430087).
引用
收藏
页码:586 / 594
页数:9
相关论文
共 35 条
  • [31] RETRACTION: The Effect of Vitamin D Supplementation on Inflammatory and Hemostatic Markers and Disease Activity in Patients with Systemic Lupus Erythematosus: A Randomized Placebo-controlled Trial (Retraction of Vol 40, Pg 265, 2013)
    Abou-Raya, Anna
    Abou-Raya, Suzan
    Helmii, Madihah
    JOURNAL OF RHEUMATOLOGY, 2018, 45 (12) : 1713 - 1713
  • [32] Effect of prebiotic and probiotic supplementation on circulating pro-inflammatory cytokines and urinary cortisol levels in patients with major depressive disorder: A double-blind, placebo-controlled randomized clinical trial
    Kazemi, Asma
    Noorbala, Ahmad Ali
    Azam, Kamal
    Djafarian, Kurosh
    JOURNAL OF FUNCTIONAL FOODS, 2019, 52 : 596 - 602
  • [33] Low-dose belimumab for patients with systemic lupus erythematosus at low disease activity: protocol for a multicentre, randomised, double-blind, placebo-controlled clinical trial
    Sun, Fangfang
    Huang, Wenyan
    Chen, Jie
    Zhao, Liling
    Zhang, Danting
    Wang, Xiaodong
    Wan, Weiguo
    Dai, Sheng-Ming
    Chen, Sheng
    Li, Ting
    Ye, Shuang
    LUPUS SCIENCE & MEDICINE, 2022, 9 (01):
  • [34] Serum Adipokine Leptin Levels in Systemic Lupus Erythematosus Patients and its Correlation with Clinical Manifestations and Disease Activity - A Cross-sectional Study from a Tertiary Care Center
    Balaji, Chilukuri
    Saranya, Chinnadurai
    Bhuvanesh, Mahendran
    Ramesh, Ramamoorthy
    Sriram, Sankaran
    Rajeswari, Sankaralingam
    INDIAN JOURNAL OF RHEUMATOLOGY, 2021, 16 (01) : 3 - 8
  • [35] The role of β-d-mannuronic acid, as a new non-steroidal anti-inflammatory drug on expression of miR-146a, IRAK1, TRAF6, NF-κB and pro-inflammatory cytokines following a clinical trial in rheumatoid arthritis patients
    Mortazavi-Jahromi, Seyed Shahabeddin
    Ahmadzadeh, Arman
    Rezaieyazdi, Zahra
    Aslani, Mona
    Omidian, Saiedeh
    Mirshafiey, Abbas
    IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2020, 42 (03) : 228 - 236